{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T21:15:46Z","timestamp":1787606146695,"version":"build-2736575974"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Since being recognized as an important drug-induced clinical entity during the 1960s, tardive dyskinesia (TD) has generated an extensive body of research seeking to understand its clinical characteristics, epidemiology, pathophysiology and management. Modern scientometric approaches allow interactive visualization of large bodies of literature to identify trends and hotspots within knowledge domains. This study thus aimed to provide a comprehensive scientometric review of the TD literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Web of Science was searched for articles, reviews, editorials and letters with the term \u201ctardive dyskinesia\u201d in the title, abstract, or keywords through 12\/31\/2021. A total of 5,228 publications and 182,052 citations were included. Annual research output, prominent research areas, authors, affiliations and countries were summarized. VOSViewer and CiteSpace were used for bibliometric mapping and co-citation analysis. Structural and temporal metrics were used to identify key publications in the network.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>TD-related publications peaked in the 1990s, gradually declined after 2004, and showed a further small increase after 2015. The most prolific authors were Kane JM, Lieberman JA, and Jeste DV overall (1968\u20132021), and Zhang XY, Correll CU and Remington G in the last decade (2012\u20132021). The most prolific journal was the Journal of Clinical Psychiatry overall, and the Journal of Psychopharmacology in the last decade. Knowledge clusters in the 1960\u20131970s dealt with clinical and pharmacological characterization of TD. In the 1980s, epidemiology, clinical TD assessment, cognitive dysfunction and animal models predominated. During the 1990s, research diverged into pathophysiological studies, especially oxidative stress, and clinical trials on atypical antipsychotics, with a focus on clozapine and bipolar disorder. In the 1990\u20132000s, pharmacogenetics emerged. More recent clusters include serotonergic receptors, dopamine-supersensitivity psychosis, primary motor abnormalities of schizophrenia, epidemiology\/meta-analyses, and advances in TD treatment, particularly vesicular monoamine transporter-2 inhibitors since 2017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This scientometric review visualized the evolution of scientific knowledge on TD over more than five decades. These findings will be useful for researchers to find relevant literature when writing scientific articles, choosing appropriate journals, finding collaborators or mentors for research, and to understand the historical developments and emerging trends in TD research.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1194222","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T11:49:11Z","timestamp":1685706551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications"],"prefix":"10.3389","volume":"14","author":[{"given":"Anuradha","family":"Baminiwatta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jns.2018.02.015","article-title":"Historical perspectives on tardive dyskinesia","volume":"389","author":"Caroff","year":"2018","journal-title":"J Neurol Sci"},{"key":"ref2","volume-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"ref3","first-page":"550","article-title":"Paroxysmal dyskinesia as the effect of megaphen","volume":"28","author":"Schonecker","year":"1957","journal-title":"Nervenarzt"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1600-0447.1964.tb05731.x","article-title":"Neurological symptoms in pharmacotherapy of psychoses","volume":"40","author":"Faurbye","year":"1964","journal-title":"Acta Psychiatr Scand"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/PRA.0000000000000224","article-title":"Tardive dyskinesia: a historical perspective","volume":"23","author":"Macaluso","year":"2017","journal-title":"J Psychiatr Pract"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet (London, England)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia","volume":"389","author":"Solmi","year":"2018","journal-title":"J Neurol Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/wps.20579","article-title":"Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis","volume":"17","author":"Carbon","year":"2018","journal-title":"World Psychiatry"},{"key":"ref10","first-page":"348","article-title":"Statistical bibliography or Bibliometrics?","volume":"25","author":"Pritchard","year":"1969","journal-title":"J Doc"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc Inf Sci Technol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euroneuro.2022.05.011","article-title":"The importance of evidence synthesis in psychopharmacology: insights from a scientometric approach","volume":"61","author":"Sabe","year":"2022","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref13","year":"2022"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"104769","DOI":"10.1016\/j.neubiorev.2022.104769","article-title":"Half a century of research on attention-deficit\/hyperactivity disorder: a scientometric study","volume":"140","author":"Cortese","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2147\/DDDT.S356284","article-title":"Global trends and hotspots in Esketamine research: a bibliometric analysis of past and estimation of future trends","volume":"16","author":"Li","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"6153","DOI":"10.3390\/ijerph19106153","article-title":"A bibliometric analysis of the literature on Irisin from 2012-2021","volume":"19","author":"Liu","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"686726","DOI":"10.3389\/fonc.2021.686726","article-title":"Knowledge domain and emerging trends in Ferroptosis research: a bibliometric and knowledge-map analysis","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/asi.4630240406","article-title":"Co-citation in the scientific literature: a new measure of the relationship between two documents","volume":"24","author":"Small","year":"1973","journal-title":"J Am Soc Inf Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0378-8733(78)90021-7","article-title":"Centrality in social networks conceptual clarification","volume":"1","author":"Freeman","year":"1978","journal-title":"Soc Networks"},{"key":"ref21","first-page":"91","article-title":"Bursty and hierarchical structure in streams","author":"Kleinberg","year":"2002"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"104608","DOI":"10.1016\/j.neubiorev.2022.104608","article-title":"Half a century of research on antipsychotics and schizophrenia: a scientometric study of hotspots, nodes, bursts, and trends","volume":"136","author":"Sabe","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1176\/ajp.124.8S.40","article-title":"Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature","volume":"124","author":"Crane","year":"1968","journal-title":"Am J Psychiatry"},{"key":"ref24","first-page":"751","article-title":"4 cases of facio-bucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics","volume":"100","author":"Sigwald","year":"1959","journal-title":"Rev Neurol (Paris)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1176\/ajp.130.1.82","article-title":"The pharmacology of tardive dyskinesias","volume":"130","author":"Klawans","year":"1973","journal-title":"Am J Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/archpsyc.1972.01750280059011","article-title":"Therapeutic approaches to tardive dyskinesia. A review of the literature","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"Kazamatsuri","year":"1973","journal-title":"Am J Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0033-3182(84)73021-0","article-title":"Incidence of tardive dyskinesia in an outpatient population","volume":"25","author":"Yassa","year":"1984","journal-title":"Psychosom J Consult Liaison Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/0010-440x(80)90018-8","article-title":"Prevalence of tardive dyskinesia in an outpatient population","volume":"21","author":"Wojcik","year":"1980","journal-title":"Compr Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","article-title":"Research diagnoses for tardive dyskinesia","volume":"39","author":"Schooler","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","article-title":"Tardive dyskinesia: prevalence and risk factors, 1959 to 1979","volume":"39","author":"Kane","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/archpsyc.1980.01780250054006","article-title":"Changes in prevalence, severity, and recovery in tardive dyskinesia with age","volume":"37","author":"Smith","year":"1980","journal-title":"Arch Gen Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/BF02244220","article-title":"Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia","volume":"101","author":"Waddington","year":"1990","journal-title":"Psychopharmacology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","volume":"13","author":"Chouinard","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"ref36","first-page":"254","article-title":"Integrating incidence and prevalence of tardive dyskinesia","volume":"22","author":"Kane","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the north American double-blind olanzapine trial","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"ref41","first-page":"5","article-title":"Tardive dyskinesia: pathophysiology and animal models","volume":"61","author":"Casey","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the guideline development Subcommittee of the American Academy of neurology","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/schbul\/18.4.701","article-title":"Gender differences in tardive dyskinesia: a critical review of the literature","volume":"18","author":"Yassa","year":"1992","journal-title":"Schizophr Bull"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1126\/science.6132447","article-title":"Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months  of neuroleptic treatment","volume":"220","author":"Waddington","year":"1983","journal-title":"Science"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0893-133X(02)00293-2","article-title":"Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism","volume":"27","author":"Lerer","year":"2002","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1532-5415.1999.tb01595.x","article-title":"Lower incidence of tardive dyskinesia with risperidone compared with haloperidol  in older patients","volume":"47","author":"Jeste","year":"1999","journal-title":"J Am Geriatr Soc"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of  atypical antipsychotics?: A new hypothesis.","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2165\/00023210-200317010-00004","article-title":"Oxidative mechanisms and tardive dyskinesia","volume":"17","author":"Lohr","year":"2003","journal-title":"CNS Drugs"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1176\/ajp.155.9.1207","article-title":"Markers of glutamatergic neurotransmission and oxidative stress associated with  tardive dyskinesia","volume":"155","author":"Tsai","year":"1998","journal-title":"Am J Psychiatry"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1176\/ajp.136.2.228","article-title":"Tardive dyskinesia and antiparkinsonian medication","volume":"136","author":"Chouinard","year":"1979","journal-title":"Am J Psychiatry"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/s0301-0082(99)00064-7","article-title":"Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?","volume":"61","author":"Andreassen","year":"2000","journal-title":"Prog Neurobiol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/309347a0","article-title":"Association with persistent neuroleptic-induced dyskinesia of regional changes in  brain GABA synthesis","volume":"309","author":"Gunne","year":"1984","journal-title":"Nature"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/archpsyc.1987.01800220077011","article-title":"Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality","volume":"44","author":"Waddington","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s0952-3278(96)90143-x","article-title":"Free radical pathology in schizophrenia: a review","volume":"55","author":"Reddy","year":"1996","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1192\/bjp.158.4.503","article-title":"The effects of clozapine on tardive dyskinesia","volume":"158","author":"Lieberman","year":"1991","journal-title":"Br J Psychiatry"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania","volume":"156","author":"Tohen","year":"1999","journal-title":"Am J Psychiatry"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/sj.mp.4000249","article-title":"Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients","volume":"2","author":"Steen","year":"1997","journal-title":"Mol Psychiatry"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/sj.mp.4002142","article-title":"Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions","volume":"13","author":"Bakker","year":"2008","journal-title":"Mol Psychiatry"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1515\/revneuro-2012-0083","article-title":"The role of serotonin in the antidyskinetic effects of deep brain stimulation: focus on antipsychotic-induced motor symptoms","volume":"24","author":"Creed","year":"2013","journal-title":"Rev Neurosci"},{"key":"ref63","first-page":"25","article-title":"Pathophysiology of antipsychotic drug-induced movement disorders","volume":"65","author":"Casey","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1017\/S0033291708004716","article-title":"Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review","volume":"39","author":"Pappa","year":"2009","journal-title":"Psychol Med"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.schres.2017.10.007","article-title":"Motor dysfunction as an intermediate phenotype across schizophrenia and other psychotic disorders: Progress and perspectives","volume":"200","author":"Hirjak","year":"2018","journal-title":"Schizophr Res"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychother Psychosom"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/JCP.0b013e31828ea95c","article-title":"Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis","volume":"33","author":"Iyo","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.2174\/1570159X19666210125152815","article-title":"Recent discussions on dopamine Supersensitivity psychosis: eight points to consider when diagnosing treatment-resistant schizophrenia","volume":"19","author":"Kanahara","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of Valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am J Psychiatry"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/wnf.0b013e3181ffde32","article-title":"Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"33","author":"Pappa","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.4088\/jcp.v68n1103","article-title":"Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study","volume":"68","author":"Lerner","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"493","DOI":"10.9758\/cpn.2020.18.4.493","article-title":"Recent advances in the pharmacology of tardive dyskinesia","volume":"18","author":"Caroff","year":"2020","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","article-title":"Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm","volume":"389","author":"Bhidayasiri","year":"2018","journal-title":"J Neurol Sci"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Jankovic","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14737175.2018.1403899","article-title":"Treatment options for chorea","volume":"18","author":"Bashir","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4088\/JCP.nu17034ah1c","article-title":"Tardive dyskinesia: recognition, patient assessment, and differential diagnosis","volume":"79","author":"Jain","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/03007995.2021.2022918","article-title":"Defining utility values for patients with tardive dyskinesia","volume":"38","author":"Ayyagari","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/JCP.0000000000001201","article-title":"RE-KINECT: a prospective Study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings","volume":"40","author":"Caroff","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/mds.26330","article-title":"NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"30","author":"O\u2019Brien","year":"2015","journal-title":"Mov Disord"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2147\/DDDT.S133205","article-title":"Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solmi","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1017\/S0033291719001296","article-title":"Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study","volume":"50","author":"Rubio","year":"2020","journal-title":"Psychol Med"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.schres.2019.11.025","article-title":"Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia","volume":"225","author":"Emsley","year":"2020","journal-title":"Schizophr Res"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S2215-0366(20)30264-9","article-title":"Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis","volume":"7","author":"Rubio","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1007\/s11192-021-03948-5","article-title":"The journal coverage of web of science, Scopus and dimensions: a comparative analysis","volume":"126","author":"Singh","year":"2021","journal-title":"Scientometrics"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jclinepi.2020.11.019","article-title":"Citation bias and other determinants of citation in biomedical research: findings from six citation networks","volume":"132","author":"Urlings","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40263-013-0067-9","article-title":"Publication bias, with a focus on psychiatry: causes and solutions","volume":"27","author":"Turner","year":"2013","journal-title":"CNS Drugs"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1194222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T11:49:22Z","timestamp":1685706562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1194222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":88,"alternative-id":["10.3389\/fpsyt.2023.1194222"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1194222","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"article-number":"1194222"}}